Stand Up To Cancer - standup2cancer.orgThis is where the end of cancer begins
   Please leave this field empty

In The News

Share this:
Email

Like this page on Facebook


Emily Whitehead Celebrates 5 Years Cancer-Free

Former SU2C cancer patient, Emily Whitehead, 12 years old and five years cancer-free, speaks up about her role as face of cancer immunotherapy.

+ More



SU2C Scientist, Dr. Baylin, Elected to National Academy of Sciences

Congratulations to Stephen Baylin, M.D., co-leader of the Van Andel Research Institute-Stand Up To Cancer Epigenetics Dream Team, who has been elected to the prestigious National Academy of Sciences! Dr. Baylin focuses on the field of epigenetics, and is currently investigating potential new therapies for colorectal cancer, acute myeloid leukemia, myelodysplastic syndrome and chronic myelomonocytic leukemia.

+ More



SU2C IRG Recipient says there is no ‘time to waste’ to find cancer cure

Melissa Skala, PhD, a 2016 recipient of an SU2C Innovative Research Grant, says the IRG program, with its quick turnaround and emphasis on results, is “the way science should be.”

+ More



Allison Named to Time’s List of 100 Most Influential People

James P. Allison, PhD, leader of the SU2C-Cancer Research Institute Cancer Immunology Dream Team, has been named to Time Magazine's list of the 100 "most influential people in the world" for his pioneering work in cancer immunology.

+ More



World Renowned Medical Oncologist Named Head of the Division of Solid Tumor Oncology

Dr. Diaz, Team Leader of the SU2C-Colorectal Cancer Dream Team: Targeting Genomic, Metabolic and Immunological Vulnerabilities of Colorectal Cancer, has been named Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering

+ More


Innovate Collaborate Accelerate
This year, approximately 1.65 million Americans will be diagnosed with cancer and about 585,720 will die of the disease.